Post by
Smokey1958 on Feb 20, 2021 10:46pm
Two More Rapid Tests....
authorized by HC. That leaves 7 more currently under review. Of the two that were authorized one requires a nasopharyngeal sample while the other requires a blood sample. While fast and meeting the sensitivity requirements both will require a medical professional to take the sample. Furthermore the sample types are not conducive to use on a mass scale.
Once again Thrm with its SCV2 device finds itself at the head of the pack in (potentially) meeting both the demand and the expectations for scaling to a mass group.
Comment by
NuTrader17 on Feb 21, 2021 11:28am
The company stock ticker is UPI. They haven't even done clinical trials yet on the very small portion of the actual company that owns the technology